Introduction
Mfs, one of the first cells to become infected with HIV, are resistant to its cytopathic effects and serve as HIV reservoirs [1] [2] [3] . Replication-competent HIV has been isolated from monocytes of HIV-infected patients, on highly active antiretroviral therapy, who have achieved increased CD4 T cell numbers and decreased viral loads of ,50 copies/ml [2, 4, 5] . Additionally, increased Mf activation in HIV-infected patients on therapy has been linked to increased microbial translocation from the gut [6, 7] . Thus, Mfs from HIV-infected patients are constantly exposed to bacterial products, such as LPS/ endotoxins [8] . Mfs constitute an important source of immunoregulatory cytokines, such as the IL-12 family of cytokines [9] . Moreover, Mfs from HIV-infected patients and Mfs infected in vitro with HIV exhibit a reduced ability to secrete various cytokines, including IL-12 [10, 11] . Thus, dysregulation of Mf function in HIV infection is an important factor in the incomplete immune recovery in HIV-infected patients on therapy. As IL-12 family cytokines are critical mediators of innate and adaptive immune responses [9] , it is important to understand whether HIV or its accessory proteins influence other members of IL-12 family cytokines, such as IL-27.
IL-27 is composed of EBI3 and p28, which share homology with the IL-12 p40 and p35 subunits, respectively [12] . IL-27 can induce pro-as well as anti-inflammatory functions through the regulation of T cell responses. It synergizes with IL-12 to enhance Th1 polarization and IFN-g production from NK cells [12] . IL-27 inhibits Th2 [13] , regulatory T [14] , and Th17 cells [15] .
Moreover, IL-27 induces proliferation, IFN-g secretion, and granzyme B production in murine and human naive CD8 T cells [16] .
In the context of HIV infection, IL-27 has been shown to inhibit HIV replication in CD4 T cells, macrophages, and PBMCs [17] [18] [19] [20] . It inhibits HIV replication indirectly through the induction of IFN-a in CD4 T cells and IFN-a and IFN-b in PBMCs, monocytes, and macrophages and subsequent induction of apolipoprotein B mRNA-editing, enzyme-catalytic, polypeptide-like 3A and 3G restriction factors [17] . IL-27 was also shown to induce directly the expression of another antiviral gene, bone marrow stromal cell antigen 2 [21] . However, the effect of HIV infection on IL-27 expression remains unknown. There is evidence that clinical characteristics, including HIV viral load, hepatitis C virus coinfection, and CD4 T cell counts, are associated with changes in serum IL-27 expression [22] , suggesting that HIV may suppress IL-27 production. However, in a recent report, plasma IL-27 levels were not significantly altered in HIV-1 infection [23] .
Tat, an immunoregulatory HIV protein, regulates viral transcription and is associated with immune dysfunction by altering cytokine production, such as TNF-a and IL-10 [24] [25] [26] [27] , and several receptors, including MHC class I [28] , b2 microglobulin [29] , and CD25 [30] . Tat has also been shown to inhibit DC functions by competing with L-type calcium channels [31] , modulating the activity of the iNOS gene in Mfs [32] , and promoting migration of monocytic cells toward infected cells [33] . Moreover, the Tat peptide interacts with TLR4-myeloid differentiation protein 2 to promote IL-10 and TNF-a production in mouse Mfs [27, 34] .
Based on the observations that IL-12 production is impaired in Mfs from HIV-infected patients and in Mfs infected in vitro with HIV [10, 11] and that circulating HIV may suppress serum IL-27 secretion [22] , we investigated whether HIV infection of Mfs would impact expression of IL-27 and its subunits and the molecular mechanism involved.
MATERIALS AND METHODS

Generation of MDMs and reagents
Blood drawn from healthy volunteers was used to isolate PBMCs, which were isolated by density gradient centrifugation over Ficoll-Hypaque (Amersham Pharmacia Biotech, Piscataway, NJ, USA). For a generation of MDMs, in brief, PBMCs (5 3 10 6 /ml) were resuspended in serum-free IMDM-10 (SigmaAldrich, St. Louis, MO, USA) and cultured in 12-well polystyrene plates (Becton Dickinson, Mississauga, ON, Canada) for 3 h to adhere to the plate. Subsequently, nonadherent cells were aspirated, and adherent cells were cultured in IMDM-10, supplemented with 10% FBS (Thermo Fisher Scientific, Waltham, MA, USA), 100 U/ml penicillin, 100 mg/ml gentamicin, 10 mM HEPES, and 2 mM glutamine (all from Sigma-Aldrich), containing 10 ng/ml (M-CSF; R&D Systems, Minneapolis, MN, USA). On day 7 postisolation, the cells were washed and cultured in IMDM-10 without any addition of M-CSF, as described earlier [35, 36] .
Tat peptides corresponding to its functional domains (Table 1) were synthesized (Biomer Technology, Pleasanton, CA, USA). SMAC mimetic AEG-730 was a gift from Dr. R. Korneluk (Apoptosis Research Centre, Ottawa, ON, Canada). Chemical inhibitors LY294002 (PI3K/Akt), SS (SHP-1), SU (Src), SP600125 (JNK), SB203580 (p38) and PD098059 (ERK) were purchased from Millipore Sigma, Billerica, MA, USA).
In vitro HIV infection of MDMs and HIV-p24 ELISA
MDMs were infected with cell-free dual-tropic HIV cs204 viral stock supernatants containing 30 ng HIV-p24 protein, supplemented with 8 mg/ml polybrene (Sigma-Aldrich) for 2 h at 37°C. The HIV-1 clinical isolate, cs204 (a gift from Dr. F. Diaz-Mitoma, Children's Hospital of Eastern Ontario, Ottawa, ON, Canada), is noncytopathic and does not cause any alteration in the growth rate or viability of infected MDMs or THP-1 cells [unpublished results] [37] . MDMs were treated in parallel with the mock viral stocks collected on the same day as the viral stock and using the same volume. Following infection, MDMs were washed and cultured for up to 15 d in complete medium. The supernatants were collected every 3-4 d for determining productive infection of MDMs by HIV-p24 ELISA. Aliquots of the mock and viral stocks were inactivated for 2 h at 37°C in 1% Triton X-100. The p24 was measured by ELISA using the HIV-1 p24 CA antigen capture assay kit, per the manufacturer's instructions (AIDS and Cancer Virus Program, National Cancer Institute, Fredrick, MD, USA). Tat 1  MEPV DPRL EPWK HPG SQPK TACT NCYC  Tat 2  QPK TACT NCYC KKCC FHCQ VCFI TKGL  Tat 3  HCQ VCFI TKGL GISY GRKK RRQR RRAP  Tat 4 RKK RRQR RRAP QDSQ THQV SLSK QPAS Tat 5 HQV SLSK QPAS QPRG DPTG PKES KKKV Tat 6 PTG PKES KKKV ERET ETDP VDQ (continued from previous page) SU = SU6656, Tat = HIV-Tat, TMB = 3,39,5,59-tetramethylbenzidine, TRAF = TNFR-associated factor, TRIF = Toll/IL-1R domain-containing adapterinducing IFN-b, VLP = virus-like particle, xIAP = X-linked inhibitor of apoptosis (Roche Applied Science, Laval, QC, Canada) and 4 mg pTat or pLXIN. The successfully transfected cells were selected with G418-supplemented medium, and supernatants were collected as described earlier [24] . Infectivity of the VLPs was confirmed by the infection of 3T3 cells (NIH Aids Research and Reference Reagent Program), cultured in 12-well plates, with serial dilutions of viral stocks in the presence of 5 mg/ml polybrene (Sigma-Aldrich). After 14 d, cells were stained with Violet Blue, and plaques were counted. MDMs were infected with pTat or pLXIN retroviruses with 3 consecutive rounds of culture with 1 ml supernatant from VLP-producing PT67 cultures in the presence of 5 mg/ml polybrene (Sigma-Aldrich) for 2 h. Cells were washed with PBS after each round and cultured in complete IMDM-10 for 48 h after the final wash.
Tat gene cloning and infection of MDMs with Tat retroviruses
b-Glo assay to determine biologic activity of intracellular Tat
The biologic activity of pTat-encoded Tat was measured using the b-Glo assay (Promega, Madison, WI, USA). In brief, TZM-bl cells were cultured with supernatants from pTat-or pLXIN-infected MDMs for 48 h in 96-well plates. The supernatant was aspirated, replaced with equal volumes of culture medium and b-Glo reagent (Promega), and incubated for 30 min before luminescence reading on a plate reader (Synergy; BioTek, Winooski, VT, USA).
RNA extraction and real-time PCR
In brief, MDMs were treated with 1 mg/ml LPS (Sigma-Aldrich) for 4 h, and total RNA was extracted using the RNeasy kit (Qiagen, Toronto, ON, Canada). cDNA was obtained by reverse transcription using the High Capacity Reverse Transcription Kit (Thermo Fisher Scientific). The cDNAs were amplified using a 7500 thermocycler using TaqMan Universal PCR Master Mix and TaqMan primers specific for b-actin (actin beta Hs99999903_mL), IL-27-EBI3 (EBI3 HS00194957_mL), and IL-27 p28 (IL-27A Hs00377366_mL; Thermo Fisher Scientific). The 7500 SDS software (Thermo Fisher Scientific) was used to calculate the CT. IL-27 p28 and EBI3 gene expression was normalized to b-actin. The D CT method was used to calculate fold change relative to uninfected, unstimulated cells, as described earlier [35] .
IL-27, IL-10, and TNF-a measurement by ELISA IL-27, TNF-a, and IL-10 were quantified using human IL-27, TNF-a (R&D Systems), and IL-10 (BD Biosciences, San Jose, CA, USA) ELISA kits, as described earlier [24, 38] . Costar high-binding 96-well ELISA plates (Corning, Corning, NY, USA) were coated overnight at 4°C in ELISA coating buffer (eBioscience, San Diego, CA, USA) with 0.4 mg/ml IL-27 capture antibody (R&D Systems). The next day, plates were washed and blocked for 2 h with production by ELISA. The mean of 7 independent replicates 6 SD is shown. In vitro HIV infection inhibits LPS-induced IL-27 p28 and EBI expression (B) and IL-27 secretion (C). Mock-treated or HIVinfected MDMs were stimulated with LPS on the indicated days for 4 h, and expression of IL-27 p28 (D5, D8, and D15: n = 5) and EBI3 mRNA (D5 and D8: n = 5, and D15: n = 4) was measured by quantitative RT-PCR. mRNA fold change was calculated relative to unstimulated, mock-treated MDMs from the same donor harvested on the same day. (C) Mock-treated or HIV-infected MDMs were stimulated on days 4, 7, and 14 postinfection with LPS for 24 h, and IL-27 in supernatants was quantified by ELISA (D5: n = 11, D8: n = 4, and D15: n = 4). Percent inhibition in HIV samples was calculated relative to mock LPS-stimulated MDMs from the matched donors (B and C, right). Results are expressed as means 6 SD. *P # 0.05; **P # 0.01; ***P # 0.001. 10% FCS in PBS, followed by the addition of standards or sample supernatants for another 24 h. On the third day, biotinylated secondary mouse anti-human mAb were added, followed by streptavidin HRP. Visualization was carried out using TMB 1, a component HRP microwell substrate solution and 450 nm liquid stop solution for TMB microwell substrates (BioFX Laboratories, Owings Mills, MD, USA). Absorbance was read using the iMark microplate reader, and data were processed using Microplate Manager 6 software (both Bio-Rad Laboratories, Hercules, CA, USA). Cytokine concentrations were determined using the regression line from a standard curve performed in duplicate with each assay. All samples were assayed in duplicate, and cytokine concentrations were expressed as nanograms per ml 6 SEM.
Western immunoblotting
Lysed cells were subjected to denaturing SDS-PAGE, followed by transfer to polyvinylidene difluoride membrane (Bio-Rad Laboratories), as described earlier [35, 36] . The primary antibodies against phospho-Akt (1/250; Cat. # 9271); Akt-1 (1/500; Cat. # 9272); phospho-p38 MAPK (1/1000; Cat. # 9211); p38 MAPK (1/1000; Cat. # 9212); phospho-ERK1/2 (Cat. # 9101); ERK-1/2 (Cat. # 4695); phospho-JNK (Cat. # 4668); JNK-1 (Cat. # 3332); cIAP-1, cIAP-2, xIAP, TRAF-1, TRAF-2, TRAF-6, MyD88, IRAK-1, IRAK-2, IRAK-4, TRIF, and pSrc (Cat. # 2105); and SHP-1 or Src (Cat. #) were all purchased from Cell Signaling Technology (Danvers, MA, USA). The murine anti-Tat antibodies (ImmunoDX, Woburn, MA, USA) were used at a concentration of 1/500. Goat anti-rabbit IgG HRP conjugate or goat anti-mouse IgG HRP conjugate was used as secondary antibodies. The immunoblots were visualized using Amersham ECL Western blotting detection reagent (GE Healthcare, Buckinghamshire, United Kingdom). The images were taken with the Chemi Genius Bio Imaging System and GeneSnap software (both from Syngene, Cambridge, United Kingdom). The loading control was detected by stripping the membrane and reprobing with the anti-GAPDH (1/1000; Sigma-Aldrich) or b-actin (1/1000; Cell Signaling Technology) antibodies.
Transient transfection
The siRNAs against cIAP-2 and TRAF-6 (Santa Cruz Biotechnology, Dallas, TX, USA; and Dharmacon, Lafayette, CO, USA) were used, as described previously [35] . In brief, the 1 ml of the control nonsilencing siRNA (QIAGEN, Mississauga, ON) and c-IAP-1 or TRAF-6 siRNA (10 ml stock solution) were incubated with 3 ml of Lipofectamine RNAiMAX (Thermo Fisher Scientific) in 200 ml of serum free OPTI-MEM for 20 min at room temperature before adding to MDMs. 24 h, cells were transferred into complete medium for 24 h, followed by stimulation with LPS (1 mg/ml) for another 24 h.
Statistical analysis
When comparisons between measurements from 2 different groups were required, the Mann-Whitney U test was used. Throughout, 2-sided P , 0.05 was considered statistically significant. All data were analyzed using GraphPad Prism (version 6.00) software (GraphPad Software, San Diego, CA, USA).
Ethics statement
Blood was obtained from healthy volunteers after approval of the protocol by the Ethics Review Committees of the Ottawa Hospital (Ottawa, ON, Canada) and Children's Hospital of Eastern Ontario. All participants gave a written consent before providing 70-80 ml blood.
RESULTS
In vitro HIV infection inhibits EBI3 and p28 mRNA expression and IL-27 production in LPS-stimulated human MDMs HIV-1 ssRNA contains sequences that can serve as TLR7 and TLR8 ligands and stimulate production of proinflammatory cytokines by DCs and Mfs [39] [40] [41] . Moreover, Mfs were shown to produce IL-27 following treatment with TLR7/8 ligands [42, 43] . Therefore, we determined whether HIV as a TLR7/8 ligand affects IL-27 production. MDMs were first infected with a dualtropic HIV cs204 strain to demonstrate productive infection (Fig.  1A) . MDMs infected in vitro with HIV cs204 were analyzed for IL-27 EBI3 and p28 mRNA expression and IL-27 production. HIV infection of unstimulated MDMs did not significantly alter either p28 or EBI3 mRNA expression or IL-27 secretion on days 5, 8, and 15 postinfection (Supplemental Fig. 1 ).
The endotoxins circulating in the blood of HIV-infected patients contribute to chronic immune activation [6, 7] . Therefore, we determined the effect of HIV on LPS-induced IL-27 production in MDMs. LPS stimulation of mock-infected MDMs significantly increased p28 and EBI3 mRNA expression and IL-27 production (Fig. 1B and C and Supplemental Fig. 2) . Interestingly, LPS-induced p28 and EBI3 mRNA expression and IL-27 production were consistently and significantly inhibited in HIV-infected MDM relative to mock-infected MDM on days 5, 8, and 15 postinfection (Fig. 1B and C) . These results suggest that HIV infection impairs TLR4-activated signaling pathways leading to inhibition of IL-27 production.
Intracellular Tat inhibits LPS-induced EBI3 and p28 mRNA expression and IL-27 production HIV-mediated inhibition of LPS-induced IL-27 production may be regulated by one of its accessory proteins, such as Tat, which has been linked to altered immune function [28, 31, 32] . We investigated the role of intracellular Tat by generating a retrovirus that encodes the Tat gene from the pSV2tat72 plasmid ligated into the pLXIN retroviral backbone. The ability of this plasmid (pTAT) to deliver the Tat gene in the PT67 packaging cell line was confirmed by PCR ( Fig. 2A, left) and immunoblotting ( Fig. 2A, right) . The biologic activity of PT67-expressed Tat was confirmed by the b-Glo assay, which uses TZM-bl cells expressing lacZ gene activity under control of an HIV-LTR promotor (Fig. 2B, left) .
The supernatant from PT67 cells containing the Tat retroviruses was used to infect MDMs. The infectivity of MDMs with the Tat retrovirus was confirmed by RT-PCR analysis ( Fig. 2A,  left) . The supernatant of pTat-infected MDMs, unlike those obtained from pLXIN-infected MDMs, activated the b-galactosidase gene in a Tat-responsive cell line, confirming the biologic activity of the transduced Tat gene (Fig. 2B, right) . Moreover, supernatants from pTat-or pLXIN-infected MDMs exhibited equal infectivity in the range of 10 2 -10 3 viral particles per milliliter, as determined by plaque assay.
To determine whether Tat protein contributes to the HIVmediated inhibition of IL-27, MDMs were infected with pTat or pLXIN retroviruses for 48 h, followed by LPS stimulation. IL-27 secretion and p28 and EBI3 mRNA expression were significantly inhibited following infection with pTat ( Fig. 3) . This was not a result of global cytokine inhibition, as TNF-a secretion, in response to LPS stimulation, was unaffected following pTat infection (Fig. 3B) . Moreover, pLXIN or pTAT viruses did not affect MDM viability. 
Extracellular Tat peptide inhibits LPS-induced IL-27 production in MDMs
Tat is released into the plasma of HIV-infected individuals [44, 45] . To determine if extracellular Tat inhibits IL-27 expression in a manner similar to that of intracellular Tat, we used Tat peptides corresponding to its domains ( Table 1) . The first exon (1-72 aa) of Tat encodes several domains and possesses full transactivation activity associated with its role in the HIV life cycle. The basic region (aa 48-60) is rich in lysine and arginine residues and has been shown to facilitate membrane transduction, assists HIV-1 reverse transcription, and augments integrin receptor binding [46] [47] [48] . The core region (aa 38-48) is required for transcriptional transactivation [49] . MDMs were treated with 6 synthetic peptides corresponding to the 6 domains of the full Tat protein (Table 1 ) before LPS stimulation. The peptides, numbers 1, 2, 4, 5, and 6, did not affect IL-27 production (Fig. 4A) . Peptide number 3, which encompasses the core and basic regions of Tat, significantly inhibited LPS-induced IL-27 protein (Fig. 4B) and IL-27 p28 and EBI3 mRNA expression ( Fig. 4C and D) in a dosedependent manner.
p38 MAPK and PI3K regulate Tat-mediated inhibition of LPS-induced IL-27 production
The above results suggest that Tat inhibits LPS-induced IL-27 production by modulating the TLR4 signaling pathway. The TLR4 signaling involved in LPS-induced IL-27 production in MDM has not been well described. Hence, we first investigated the TLR4 signaling involved in IL-27 production in pLXIN-infected MDMs. The MAPK pathway has been shown to regulate LPSinduced IL-27 production in astrocytes and myeloid DCs [50] . The role of p38 MAPK was determined by using SB203580, a p38-specific chemical inhibitor. It significantly inhibited LPSinduced p38 phosphorylation (Fig. 5A, upper) and IL-27 production in pLXIN-infected MDMs (Fig. 5A, lower) . The involvement of p38 MAPK in IL-27 regulation was confirmed by its siRNA (data not shown). We next determined whether Tatmediated inhibition of LPS-induced IL-27 production occurs via p38 phosphorylation. The basal levels of p38 phosphorylation were similar in pLXIN-and Tat-infected MDMs. However, LPSinduced p38 phosphorylation was inhibited in Tat-infected MDMs (Fig. 5B) .
As Tat and SB203580 inhibit LPS-induced p38 phosphorylation and IL-27 production, we determined if inhibition of p38 phosphorylation, mediated by Tat, would synergize with SB203580 to inhibit further LPS-induced IL-27 production. For this, Tat-infected MDMs were treated with SB203580 before LPS stimulation. As expected, Tat inhibited LPS-induced IL-27 production (Fig. 5C ). LPS-induced IL-27 production in SB203580-pretreated, Tat-infected MDMs was further inhibited compared with the untreated, Tat-infected MDMs (Fig. 5C ).
To determine a potential role for Erk and JNK MAPKs in LPSinduced IL-27 production, PD098059 and SP600125, the ERKand JNK-specific inhibitors, respectively, were used. The biologic activity of SP600125 and PD098059 was first confirmed (Fig. 5D  and G, upper) . The ERK and JNK MAPKs did not regulate LPSinduced IL-27 production, as PD098059 and SP600125 did not affect LPS-induced IL-27 production in pLXIN-infected MDMs ( Fig. 5D and G, lower) . Interestingly, LPS-induced ERK but not JNK phosphorylation was significantly inhibited in Tat-infected MDMs ( Fig. 5E and H) . We next determined if Tat would cooperate with PD098059 or SP600125 to affect LPS-induced IL-27 production. For this, Tat-infected MDMs were treated with PD098059 or SP600125 before LPS stimulation. As expected, Tat-infected MDMs exhibited significantly decreased LPSinduced IL-27 production compared with the pLXIN-infected MDMs ( Fig. 5F and I ). PD098059 and SP600125 did not further inhibit LPS-induced IL-27 production in Tat-infected MDMs ( Fig. 5F and I ).
The PI3K/Akt pathway has also been shown to regulate LPSinduced IL-27 production in human astrocytes and DCs [51] . The role of PI3K/Akt was determined by using LY294002, a PI3K/Akt-specific chemical inhibitor. The biologic activity of LY294002 was confirmed (Fig. 6A, left) . LY294002 significantly inhibited LPS-induced IL-27 production in pLXIN-infected MDMs (Fig. 6A, right) . As LY294002 has some nonspecific effects, especially at a high concentration [52] , the involvement of Akt in IL-27 regulation was confirmed by its siRNA (data not shown). We next demonstrated that Tat-mediated inhibition of LPS-induced IL-27 production occurs via Akt activation, as (Fig. 6B) . We next determined if Akt inhibition by Tat would synergize with LY294002 to inhibit further LPS-induced IL-27 production. For this, Tat-infected MDMs were treated with LY294002 before LPS stimulation. As expected, LPS-induced IL-27 production was significantly inhibited in pTat-infected MDMs (Fig. 6C) . Treatment with LY294002 further significantly inhibited LPS-induced IL-27 production in pTat-infected MDM (Fig. 6C) . Overall, the results suggest that Tat is a potent inhibitor of p38 MAPK and Akt phosphorylation, and along with SB203580 or LY294002, it further inhibits LPS-induced IL-27 production in MDMs.
LPS-induced Akt phosphorylation was decreased significantly in Tat-infected MDMs compared with the pLXIN-infected MDMs
Extracellular Tat inhibits LPS-induced p38 phosphorylation through PI3K activation
We next demonstrated that peptide number 3, corresponding to the core and basic region of Tat, inhibited LPS-induced p38 MAPK and Akt activation in a manner similar to that of intracellular Tat (Fig. 7A) . To determine if LPS-activated p38 and Akt pathways acted as a single or as 2 parallel independent pathways in the inhibition of IL-27 production, LY294002-treated MDMs were stimulated with LPS and analyzed for p38 phosphorylation. LY294002 inhibited LPS-induced p38 phosphorylation in a dose-dependent manner (Fig. 7B) , suggesting that peptide number 3 inhibits LPS-induced IL-27 production by inhibiting an Akt-activated p38 MAPK pathway.
Src and SHP-1 regulate LPS-induced IL-27 production but do not contribute to Tat-mediated inhibition of LPS-induced IL-27 production TLR4 activation triggers tyrosine phosphorylation of several protein tyrosine kinases, including Src kinases and phosphatases, such as SHP-1 [53] [54] [55] . However, the role of Src and SHP-1 in LPS-induced IL-27 production is not known. For this, SU and SS, specific inhibitors of Src and SHP-1, respectively, were used and their biologic activities confirmed (Fig. 8A and C, upper) . LPS-induced IL-27 production was inhibited by both SU and SS in a dosedependent manner (Fig. 8A and C, lower) . As these chemical inhibitors have off-target effects, especially when used at high concentrations, the involvement of SHP-1 and Src in IL-27 regulation was confirmed by their respective siRNAs (data not shown). However, in contrast to p38 MAPK and PI3K, pTat infection did not affect LPS-induced Src or SHP-1 activation (Fig. 8B and D, upper) . Although Tat did not inhibit Src or SHP-1 activation, it may still cooperate with SU or SS to inhibit LPS-induced IL-27 production. For this, Tat-infected MDMs were treated with SU or SS before LPS stimulation. As expected, pTat significantly inhibited LPS-induced IL-27 production. Interestingly, LPS-induced IL-27 production in pLXIN and Tat-infected MDMs, in the presence of 2.5 and 5 mM SU (Fig. 8B, lower) or 400 and 600 mM of SS (Fig.  8D, lower) , was significantly inhibited. These results suggest that Src and SHP-1 inhibitors cooperate with Tat to inhibit further LPS-induced IL-27 production.
Tat impairs LPS signaling via the cIAP-1-TRAF-6 complex upstream of PI3K and MAPK Upon LPS stimulation, TLR4 recruits a series of MyD88-dependent and independent proteins that consequently transduce signals to downstream PI3K and MAPK [56] , which may be impacted by Tat. We demonstrated similar levels of MyD88, TRIF, TRAF-3, IRAK-1, IRAK-3, IRAK-4, TRAF-2, cIAP-2, and xIAP in pLXIN-and pTat-infected MDMs (Fig. 9A) . LPS induced the expression of TRAF-1, IRAK-1, IRAK-3, and cIAP-2; however, infection with pTat retroviruses did not alter their expression (Fig. 9A) .
Although LPS stimulation did not affect the expression of cIAP-1 and TRAF-6 in pLXIN-infected cells, infection with pTat retroviruses decreased the expression of TRAF-6 (Fig. 9B, upper) and cIAP-1 (Fig. 9D, top) . Likewise, treatment with Tat peptide number 3 decreased the expression of TRAF-6 (Fig. 9B, lower) and cIAP-1 (Fig. 9D, middle) , suggesting their involvement in LPS-induced IL-27 production. We determined the role of TRAF-6 in LPS-induced IL-27 production by silencing TRAF-6 expression using siRNA. The silencing of TRAF-6 expression significantly reduced LPS-induced IL-27 production in MDMs (Fig. 9C) . Similar to TRAF-6, silencing of cIAP-1 by SMAC mimetics inhibited LPS-induced IL-27 production (Fig. 9D,  bottom) . As TRAF-6 and cIAP form a complex [57] , our results suggest that Tat inhibits LPS-induced IL-27 production through the inhibition of the cIAP-1-TRAF-6 complex and downstream PI3K-activated p38 MAPKs.
In vitro HIV infection inhibits p38 MAPK phosphorylation in LPS-stimulated MDMs
The above results show that Tat inhibits LPS-induced IL-27 production through cIAP-1, TRAF-6, PI3K, and p38 MAPK in MDMs and that in vitro infection with HIV inhibits LPS-induced IL-27 production in MDMs. To elucidate the signaling pathway by which HIV inhibits LPS-induced IL-27 production, the activation of cIAP-1, TRAF-6, PI3K, and p38 was investigated in HIV-infected MDMs. As HIV significantly inhibited LPS-induced p28 and EBI3 mRNA expression and IL-27 production on day 5 postinfection (Fig. 1) , this time was used to determine their level of expression. LPS-induced p38 phosphorylation was inhibited by 50% in HIV-infected MDMs compared with the controls (Fig. 10A) . However, the basal levels of p38 phosphorylation and the basal and LPS-stimulated levels of phospho-Akt (Fig. 10B ) and cIAP-1 and TRAF-6 (data not shown) were not different between mock-and HIV-infected MDMs. As LPSinduced IL-27 production is positively regulated by p38 MAPKs, and HIV inhibits p38 phosphorylation in HIV-infected MDMs stimulated with LPS, these results suggest that HIV may inhibit LPS-induced IL-27 production in MDMs by inhibiting the p38 pathway alone.
DISCUSSION
We show that in vitro HIV infection and Tat inhibit LPS-induced IL-27 production in human MDMs, suggesting that HIV and Tat interfere with the TLR4 signaling pathway. To understand the role of this signaling pathway, we demonstrated that Tat causes down-regulation of cIAP-1 and TRAF-6 and decreases phosphorylation of downstream PI3K and p38 MAPKs, which are implicated in LPS-induced IL-27 production. In contrast to Tat, in vitro HIV infection of MDMs inhibits IL-27 production via p38 MAPK inhibition alone.
HIV infection has been shown to influence responsiveness of myeloid cells to TLR stimulation [58] [59] [60] [61] . For example, HIVinfected Mfs produced significantly higher levels of TNF-a, IL-6, and IL-1 in response to TLR3, -4, and -7/8 ligands [58] . In contrast, pretreatment of murine Mfs with a TLR8 agonist (R848) or HIV ssRNA rendered these cells tolerant to restimulation with the same ligand, resulting in decreased MIP1b production [59] . Likewise, alveolar Mfs from HIV-infected individuals exhibited decreased TNF-a production in response to stimulation via TLR4 [60] . Our results show that although in vitro HIV infection does not alter basal levels of IL-27 or its subunits, LPS-induced IL-27 EBI3 and p28 mRNA and IL-27 production are significantly inhibited. Decreased IL-27 production may have a role in HIV pathogenesis. As Tat is present in the circulation [44, 45] , myeloid cells, including monocytic cells, are constantly exposed to the circulating Tat. There is also evidence for the presence of LPS/endotoxin in the circulation and persistent activation of macrophages in HIV-infected individuals [6] [7] [8] . Therefore, Tat may inhibit LPS/endotoxin-induced activation of monocytic cells and production of proinflammatory cytokines. IL-27 also synergizes with IL-12 to enhance IFN-g production from NK and Th1 cells [12] . Hence, a Tat-mediated decrease in IL-27 production may result in decreased production of IFN-g and possibly other proinflammatory cytokines and dampening of inflammation caused by circulating endotoxin. Moreover, IL-27 inhibits HIV replication [17] [18] [19] [20] . Therefore, inhibition of IL-27 may result in increased HIV replication and decreased Th1-type cell-mediated immune responses. Although the main function of Tat is to transactivate the LTR of the integrated HIV genome [62] , Tat is known to impair a variety of immune functions; e.g., it enhances IL-10, TNF-a, and IL-6 production in primary monocytes [24, 25, [63] [64] [65] , modulates cytokine expression in T cells, causes impaired T cell signaling [27, 66, 67] , and affects various functions of APCs [28, 31, 32, 68, 69] . Tat is expressed intracellularly in HIV-infected cells and is also released into the plasma and culture supernatants of infected cells [44, 45] . Exogenous Tat readily crosses the cell membranes [70] , and the central basic domain has been implicated in mediating this transport and its subsequent translocation and accumulation in the nucleus [46] . We observed a relatively low level of Tat activity in MDMs that can be attributed to its very short half-life and its propensity to lose biologic activity [71] . In fact, it is generally difficult to detect Tat in the culture supernatants from chronically infected myeloid cells or cell lines permanently expressing Tat (H9 and U937) [44] . Expression of Tat in our cell system may mimic Tat expression in myeloid cells. Tat protein has been shown to induce TNF-a production [26, 27, 34] . The reason why we did not observe TNF-a production in Tat virus-infected, unstimulated MDMs (Fig. 3) is not clear but may be a result of different cell types used or because of low biologic activity of the Tat. To infect MDMs, we have not used purified Tat but rather Tat viruses straight from the supernatants of PT-67 cells, which contain cytokines/chemokines that may have blocked TNF-a production.
IL-27 p28 is regulated in human DCs by IRF-3 [72] and by IRF-1 in RAW264.7 macrophages [73] . IFN-g-induced IL-27 production was shown to be regulated by the JNK MAPK in human monocytic cells [38] , suggesting that distinct signaling molecules regulate IL-27 production depending on the cell type and the MDMs were transfected with TRAF-6 siRNAs for 48 h, followed by stimulation with LPS for 24 h. Cell lysates were analyzed for TRAF-6 expression by Western blot analysis (upper; n = 3). MDMs were transfected with TRAF-6 siRNAs for 48 h, followed by stimulation with LPS for 24 h (lower; n = 6). The supernatants were analyzed for IL-27 production by ELISA. Results are expressed as means 6 SD. Ctl/ctrl, Control. (D) cIAP-1 regulated Tat-mediated inhibition of LPS-induced IL-27 production. The pLXIN-and pTat-infected MDMs were stimulated with LPS for 24 h, followed by Western blot analysis for cIAP-1 expression (top). MDMs were treated with various concentrations of SMAC mimetic LCL161 (LCL) for 3 h, followed by LPS stimulation for 24 h (bottom; n = 4). The supernatants were analyzed for IL-27 production by ELISA and results expressed as means 6 SD. stimulus used. Hence, we first demonstrated in the setting of human MDMs infected with pLXIN retroviruses that LPSinduced IL-27 production is regulated by cIAP-1, TRAF-6, PI3K, and p38 MAPK and upstream SHP-1 and Src kinases. Furthermore, Tat inhibits LPS-induced IL-27 secretion by inhibiting PI3K/Akt and p38 MAPK activity. However, Yim et al. [69] observed inhibition of LPS-induced ERK but not p38 phosphorylation in recombinant Tat-treated monocytes. The reason for this difference may be a result of the different cell types used. We also observed that SHP-1 and Src kinases regulate LPS-induced IL-27 production; however, Tat did not inhibit these kinases and hence, was not involved in Tat-mediated inhibition of LPSinduced IL-27 production.
We determined further whether Tat also affects upstream mediators of the TLR4 pathway. In one study, MyD88-dependent signals, such as IRAK-1, MyD88, and NF-kB activation, were reduced in alveolar Mfs from asymptomatic HIV-infected individuals, whereas MyD88-independent signals, including IRF-3 activation, were unaffected [61] . We show that among the TLR4-associated kinases investigated, the expression of cIAP-1 and TRAF-6 in unstimulated, as well as LPS-stimulated, MDMs is reduced in the presence of intracellular or extracellular Tat, which implicates these molecules as proximal Tat targets responsible for inhibition of LPS-induced IL-27 production. We have not investigated the effect of Tat on cIAP-1 and TRAF-6 expression in primary monocytes or other cells that are resistant to HIV infection and at the same time are responsive to TLR ligands. As in vitro HIV infection of MDM inhibits IL-27 production by p38 MAPK compared with the broader range of intermediate signaling kinases by Tat, circulating Tat may have a greater impact on endotoxin/LPS-induced production of cytokines compared with HIV infection. How Tat down-regulates cIAP-1 and TRAF-6 expression is not known. Tat is known to interact with NF-kB and specificity protein 1 [74] [75] [76] and the cytoplasmic tail of CD127 and eventually target it for degradation in CD8 + T cells [77] . As cIAP-1/TRAF-6 play a crucial role in LPS signaling [78] , their down-regulation by Tat may lead to decreased activation of PI3K/Akt and p38 MAPKs and inhibition of LPS-induced IL-27 production. We have not analyzed the inhibitory effects of other viral proteins, such as nef or Vpr, on the LPS-induced activation of the above-mentioned kinases. Hence, the inhibitory effects of Vpr/nef on LPS-induced IL-27 production or activation of such kinases cannot be ruled out.
Although HIV is known to impair immune function, the precise signaling pathways that are dysregulated are not well understood. Our results show that contrary to Tat, in vitro HIV infection significantly reduced only LPS-induced p38 phosphorylation without impacting Akt phosphorylation and expression of cIAP-1 and TRAF-6. HIV encodes several accessory proteins, which may exert a compensatory increase in Akt activation and expression of cIAP-1 and TRAF-6 and mask the effect of Tat on the cIAP-1-TRAF-6-PI3K axis. Indeed, HIV-Vpr was shown to induce Akt activation in human astrocytes [79] . However, the involvement of other possible pathways in HIV-infected cells cannot be ruled out.
IRF-3 and IRF-1 regulate IL-27 p28 expression in human DCs following stimulation with TLR ligands [72] and IFN-b [80] , respectively, whereas IRF-1-NF-kB mediated LPS-induced IL-27 p28 expression in RAW264.7 macrophages [73] . Furthermore, TLR2, -3, and -7/8 ligands regulated IL-27 p28 gene expression in human macrophages through IFN-a and possibly through IRF-1 activation [42, 43] . Tat is known to activate NF-kB by enhancing the p65 transcriptional activity and by physically interacting with the IkBa repressor IkBa and p65 [75, 76, [81] [82] [83] . Our results show that HIV peptide number 3 (34-60 aa) did not activate NFkB in MDMs (data not shown). This is consistent with a report that showed that NF-kB was not activated by Tat peptides 20-72 and 30-72 aa [64] . This is also consistent with our results showing that Tat peptide number 3 did not induce IL-27 p28 and EBI3 mRNAs that are regulated, at least in part, by NF-kB [73, 84] . Thus, HIV infection and Tat may inhibit LPS-induced IL-27 production by inhibiting activation of IRFs and NF-kB indirectly through the inhibition of the upstream p38 MAPK, PI3K/Akt, cIAP-1, and TRAF-6 kinases in MDMs.
In summary, we demonstrate for the first time that HIV and Tat significantly inhibit LPS-induced IL-27 production in in vitro HIV-infected human macrophages. As IL-27 has multiple roles in T cell regulation and cell-mediated immunity and is capable of inhibiting HIV replication, IL-27 inhibition in HIV infection may be associated with decreased, HIV-specific immune responses, inflammation, and increased viral replication. These findings support further investigation of how to relieve this inhibition with the goal of better controlling viral replication and restoring normal T cell function in HIV infection. 
